ABIVAX
€83.50Change from previous close: −0.77%Absolute change: −€0.65
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Selling, general and administrative | 27.0 | 8.0 | 27.7 | 27.3 | 8.9 | — |
| Research and development | 58.3 | 49.5 | 44.4 | 55.4 | 38.6 | — |
| Operating income | -84.1 | -56.2 | -71.6 | -80.7 | -46.5 | — |
| EBIT | -123 | -45.7 | -60.8 | -149 | -44.9 | — |
| EBITDA | -122 | -45.3 | -60.6 | -149 | -44.6 | — |
| Interest expense | 0.7 | 2.5 | 15.3 | 4.2 | 3.5 | — |
| Pre-tax income | -124 | -48.2 | -76.1 | -153 | -48.4 | — |
| Income tax | -6.1 | 0.2 | 5.8 | 0.0 | 0.0 | — |
| Net income | -117 | -48.5 | -82.0 | -153 | -48.4 | — |
| Net income to common shareholders | -117 | -48.5 | -82.0 | -153 | -48.4 | — |
| Basic EPS | -1.47 | -0.61 | — | -2.10 | -0.76 | -0.83 |
| Diluted EPS | -1.47 | -0.61 | — | -2.10 | -0.76 | -0.83 |
| Average shares (basic) | 79.6 | 79.0 | — | 72.9 | 63.4 | 63.4 |
| Average shares (diluted) | 79.6 | 79.0 | — | 72.9 | 63.4 | 63.4 |